Abilify Maintena shows superior efficacy to paliperidone palmitate

4 November 2014

Danish CNS specialist Lundbeck (LUND: C) and the US subsidiary of Japan’s Otsuka Pharmaceutical (TYO: 4768) have released positive results from the QUALIFY study; the first trial of its kind comparing two atypical long-acting injectable anti-psychotic therapies in a close-to-real life setting.

The effectiveness of Abilify Maintena (aripiprazole extended-release injectable suspension, for intramuscular use) and paliperidone palmitate once-monthly (paliperidone palmitate extended-release injectable suspension, for intramuscular use) in adult patients with schizophrenia was measured by the Heinrichs-Carpenter Quality of Life Scale (QLS; primary endpoint). QLS is clinician-rated scale designed to evaluate social functioning and behavior in patients with schizophrenia.

Statistically-significant improvement in the QLS total score

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK